US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

eXoZymes Inc

7.15

+0.11001.56%

Post-market: 7.150.00000.00%19:30 EDT

Volume:10.23K

Turnover:76.18K

Market Cap:66.36M

PE:-5.94

High:8.01

Open:8.01

Low:7.08

Close:7.04

52wk High:18.40

52wk Low:4.35

Shares:9.28M

Float Shares:7.20M

Volume Ratio:1.27

T/O Rate:0.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2028

EPS(LYR):-1.0927

ROE:-187.16%

ROA:-74.74%

PB:18.16

PE(LYR):-6.54

Loading ...

Overview Company News Filings

Exozymes Says Optimized NCT Process Lifts Manufacturing Productivity 10-Fold

Exozymes FY26 Q2 Net Loss Widens 22% to $2.88 Million; Revenue Remains no Revenue

eXoZymes Menjadwalkan Konferensi Pers Kuartal II 2026 Lewat Webinar

NASDAQ Trade Halt Volatility Trading Pause at 09:35 Am

Exozymes Prices Registered Direct Offering at USD 18 Per Unit, Raising USD 639,990 Gross

Exozymes Wins USD 2.03 Million NIH Grant for Cannabinoid Analog Development

Exozymes Wins NIH Grant Worth $2.03 Million for Cannabinoid Analog Development

eXoZymes closes USD 5.95 million follow-on offering of stock and warrants

EXoZymes Prices $5.3 Million Offering

MT Newswires Live

eXoZymes prices 592,270 shares at $18.00 in public offering

eXoZymes prices public offering of stock-warrant units at $18, raising $5.33 million gross

Exozymes Q1 FY26 net loss widens 27.7% to $2.37 million

eXoZymes announces graduation from Shell GameChanger Accelerator

Exozymes CSO Tyler Korman disposes of USD 15,424 common shares

eXoZymes CCO says NCTx targets supplement launch for NCT, eyes pharma options

BRIEF-Exozymes Inc - Announces Common Stock Offering - SEC Filing

Exozymes files Form 3 for Chief Commercial Officer Damien Perriman

eXoZymes Inc. - Common Stock Q4 EPS $(0.31)

Benzinga Earnings

MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter

Exozymes FY25 net loss widens 56.3% to $9.2 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/EXOZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EXOZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXOZ\",,,,,undefined,":{"symbol":"EXOZ","market":"US","secType":"STK","nameCN":"eXoZymes Inc","latestPrice":7.15,"timestamp":1787342400000,"preClose":7.04,"halted":0,"volume":10232,"hourTrading":{"tag":"盘后","latestPrice":7.15,"preClose":7.15,"latestTime":"19:30 EDT","volume":12,"amount":85.82,"timestamp":1787355007394,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.015625000000000045,"floatShares":7200200,"shares":9281359,"eps":-1.202818,"marketStatus":"Market Closed","change":0.11,"latestTime":"08-21 16:00:00 EDT","open":8.01,"high":8.01,"low":7.08,"amount":76183.2287896,"amplitude":0.132102,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.202818,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1731474000000,"exchange":"NASDAQ","adjPreClose":7.04,"preHourTrading":{"tag":"盘前","latestPrice":7.69,"preClose":7.04,"latestTime":"09:26 EDT","volume":416,"amount":3172.8297536,"timestamp":1787318788968,"change":0.65,"changeRate":0.09233,"amplitude":0.255682},"postHourTrading":{"tag":"盘后","latestPrice":7.15,"preClose":7.15,"latestTime":"19:30 EDT","volume":12,"amount":85.82,"timestamp":1787355007394,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.267277687724933},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EXOZ\",,,,,undefined,":{"symbol":"EXOZ","floatShares":7200200,"roa":"-74.74%","roe":"-187.16%","lyrEps":-1.092739,"volumeRatio":1.267277687724933,"shares":9281359,"dividePrice":0,"high":8.01,"amplitude":0.132102,"preClose":7.04,"low":7.08,"week52Low":4.35,"pbRate":"18.16","psRate":"-94802.45","week52High":18.4,"institutionHeld":0,"latestPrice":7.15,"eps":-1.202818,"divideRate":0,"volume":10232,"delay":0,"ttmEps":-1.202818,"open":8.01,"prevYearClose":10.9,"prevWeekClose":5.82,"prevMonthClose":4.65,"prevQuarterClose":8.43,"fiveDayClose":5.82,"twentyDayClose":4.71,"sixtyDayClose":9.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EXOZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EXOZ","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"","actualEps":-0.33},{"market":"US","date":"2026-05-14","symbol":"EXOZ","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"","actualEps":-0.28},{"market":"US","date":"2026-03-30","symbol":"EXOZ","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2025-11-13","symbol":"EXOZ","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-08-12","symbol":"EXOZ","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EXOZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EXOZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EXOZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EXOZ","date":"2026-08-21","current":-5.944374,"percent":0.927765,"low":-38.160378,"twenty":-18.820002,"median":-12.832819,"eighty":-8.692392,"high":-3.857052,"avg":-14.86308,"sd":7.684457,"marketCap":65340767},"quantilePoints":[{"date":"2024-11-15","current":-17.638065,"twenty":-16.673681,"median":-16.303004,"eighty":-13.514057,"marketCap":90376120},{"date":"2024-11-22","current":-27.709046,"twenty":-24.897229,"median":-17.820473,"eighty":-15.786455,"marketCap":141979075},{"date":"2024-11-29","current":-23.431811,"twenty":-26.228751,"median":-23.803745,"eighty":-16.380753,"marketCap":120062842},{"date":"2024-12-06","current":-24.621998,"twenty":-25.324953,"median":-23.431811,"eighty":-17.155873,"marketCap":126161272},{"date":"2024-12-13","current":-28.211156,"twenty":-27.188339,"median":-24.50112,"eighty":-17.856955,"marketCap":144551850},{"date":"2024-12-20","current":-34.534026,"twenty":-28.97362,"median":-25.049722,"eighty":-19.307588,"marketCap":176949760},{"date":"2024-12-27","current":-37.397914,"twenty":-31.565997,"median":-26.072539,"eighty":-21.233684,"marketCap":191624107},{"date":"2025-01-03","current":-27.113953,"twenty":-30.517181,"median":-26.965179,"eighty":-22.844156,"marketCap":138929860},{"date":"2025-01-10","current":-21.20021,"twenty":-29.84785,"median":-26.072539,"eighty":-22.501977,"marketCap":108628285},{"date":"2025-01-17","current":-19.638089,"twenty":-29.457134,"median":-25.39376,"eighty":-20.177393,"marketCap":100624096},{"date":"2025-01-24","current":-25.012528,"twenty":-29.397624,"median":-24.882351,"eighty":-20.355921,"marketCap":128162319},{"date":"2025-01-31","current":-31.168028,"twenty":-29.639419,"median":-25.737799,"eighty":-20.445185,"marketCap":159702637},{"date":"2025-02-07","current":-29.884857,"twenty":-31.406065,"median":-26.053942,"eighty":-20.902663,"marketCap":153127767},{"date":"2025-02-14","current":-36.114743,"twenty":-32.547901,"median":-26.816406,"eighty":-21.058875,"marketCap":185049237},{"date":"2025-02-21","current":-32.934712,"twenty":-32.934712,"median":-27.113953,"eighty":-21.148139,"marketCap":168754994},{"date":"2025-02-28","current":-31.428381,"twenty":-32.934712,"median":-27.625361,"eighty":-21.746952,"marketCap":161036669},{"date":"2025-03-07","current":-26.927986,"twenty":-32.733868,"median":-27.709046,"eighty":-22.345765,"marketCap":137976980},{"date":"2025-03-14","current":-28.545897,"twenty":-32.577656,"median":-27.532377,"eighty":-22.691663,"marketCap":146267033},{"date":"2025-03-21","current":-27.541676,"twenty":-32.551621,"median":-27.541676,"eighty":-22.896227,"marketCap":141121483},{"date":"2025-03-28","current":-18.578079,"twenty":-32.488392,"median":-27.318516,"eighty":-22.691663,"marketCap":95192682},{"date":"2025-04-04","current":-14.204905,"twenty":-32.395408,"median":-26.927986,"eighty":-21.047717,"marketCap":83259709},{"date":"2025-04-11","current":-15.561153,"twenty":-32.347057,"median":-26.881494,"eighty":-20.08069,"marketCap":91209129},{"date":"2025-04-17","current":-15.475495,"twenty":-32.280109,"median":-26.825611,"eighty":-19.083908,"marketCap":90707060},{"date":"2025-04-25","current":-15.318456,"twenty":-32.034633,"median":-26.407279,"eighty":-17.783991,"marketCap":89786601},{"date":"2025-05-02","current":-15.546876,"twenty":-31.65898,"median":-25.988854,"eighty":-16.786058,"marketCap":91125450},{"date":"2025-05-09","current":-18.573449,"twenty":-31.439539,"median":-25.049722,"eighty":-16.354836,"marketCap":108865208},{"date":"2025-05-16","current":-18.757829,"twenty":-31.32424,"median":-24.714982,"eighty":-16.354836,"marketCap":125851862},{"date":"2025-05-23","current":-18.209062,"twenty":-30.974622,"median":-24.436031,"eighty":-16.569406,"marketCap":122170026},{"date":"2025-05-30","current":-17.336025,"twenty":-30.684514,"median":-24.380241,"eighty":-16.780348,"marketCap":116312559},{"date":"2025-06-06","current":-17.061642,"twenty":-30.529046,"median":-23.441109,"eighty":-16.780348,"marketCap":114471640},{"date":"2025-06-13","current":-16.400628,"twenty":-29.90271,"median":-22.948297,"eighty":-16.721282,"marketCap":110036701},{"date":"2025-06-20","current":-15.402871,"twenty":-29.884857,"median":-22.501977,"eighty":-16.400628,"marketCap":103342453},{"date":"2025-06-27","current":-12.12948,"twenty":-29.84785,"median":-21.135121,"eighty":-16.003718,"marketCap":81380299},{"date":"2025-07-03","current":-12.359713,"twenty":-29.639419,"median":-20.735293,"eighty":-15.802318,"marketCap":82924997},{"date":"2025-07-11","current":-12.496904,"twenty":-29.483169,"median":-20.177393,"eighty":-15.6911,"marketCap":83845456},{"date":"2025-07-18","current":-11.536563,"twenty":-29.397624,"median":-19.545105,"eighty":-15.486916,"marketCap":77402242},{"date":"2025-07-25","current":-12.409601,"twenty":-29.129833,"median":-18.888784,"eighty":-15.347008,"marketCap":83259709},{"date":"2025-08-01","current":-12.59668,"twenty":-29.036849,"median":-18.782773,"eighty":-15.15285,"marketCap":84514881},{"date":"2025-08-08","current":-12.484432,"twenty":-28.955024,"median":-18.583221,"eighty":-14.399063,"marketCap":83761778},{"date":"2025-08-15","current":-10.86886,"twenty":-28.847163,"median":-18.391255,"eighty":-12.940906,"marketCap":83788627},{"date":"2025-08-22","current":-10.129037,"twenty":-28.601687,"median":-18.146703,"eighty":-12.680718,"marketCap":78085297},{"date":"2025-08-29","current":-10.553347,"twenty":-28.278104,"median":-17.797382,"eighty":-12.592988,"marketCap":81356325},{"date":"2025-09-05","current":-11.505325,"twenty":-28.18884,"median":-17.655417,"eighty":-12.491915,"marketCap":88695168},{"date":"2025-09-12","current":-13.490877,"twenty":-28.107015,"median":-17.448273,"eighty":-12.538062,"marketCap":104001900},{"date":"2025-09-19","current":-14.959642,"twenty":-27.850381,"median":-17.370635,"eighty":-12.573133,"marketCap":115324687},{"date":"2025-09-26","current":-15.847102,"twenty":-27.608624,"median":-17.061642,"eighty":-12.589297,"marketCap":122166167},{"date":"2025-10-03","current":-14.479193,"twenty":-27.541676,"median":-16.87379,"eighty":-12.59668,"marketCap":111620877},{"date":"2025-10-10","current":-14.687648,"twenty":-27.530518,"median":-16.831742,"eighty":-12.611646,"marketCap":113227875},{"date":"2025-10-17","current":-13.708472,"twenty":-27.277603,"median":-16.76567,"eighty":-12.63659,"marketCap":105679350},{"date":"2025-10-24","current":-13.055688,"twenty":-27.024689,"median":-16.432585,"eighty":-12.67218,"marketCap":100647000},{"date":"2025-10-31","current":-13.758627,"twenty":-26.942863,"median":-16.351816,"eighty":-12.69627,"marketCap":106066002},{"date":"2025-11-07","current":-14.687648,"twenty":-26.927986,"median":-16.160757,"eighty":-12.7049,"marketCap":113227875},{"date":"2025-11-14","current":-17.842773,"twenty":-26.927986,"median":-16.281848,"eighty":-12.745787,"marketCap":137550900},{"date":"2025-11-21","current":-15.99071,"twenty":-26.872196,"median":-16.260691,"eighty":-12.78526,"marketCap":133357275},{"date":"2025-11-28","current":-15.960539,"twenty":-26.834928,"median":-16.09128,"eighty":-12.82517,"marketCap":133105657},{"date":"2025-12-05","current":-15.085575,"twenty":-26.827452,"median":-15.997214,"eighty":-12.905985,"marketCap":125808750},{"date":"2025-12-12","current":-15.99071,"twenty":-26.816406,"median":-15.99071,"eighty":-12.979888,"marketCap":133357275},{"date":"2025-12-19","current":-12.269601,"twenty":-26.652755,"median":-15.960539,"eighty":-12.82517,"marketCap":102324450},{"date":"2025-12-26","current":-12.541142,"twenty":-26.340331,"median":-15.88442,"eighty":-12.702264,"marketCap":104589007},{"date":"2026-01-02","current":-10.962185,"twenty":-26.072539,"median":-15.879825,"eighty":-12.621624,"marketCap":91421025},{"date":"2026-01-09","current":-9.735225,"twenty":-26.035346,"median":-15.826918,"eighty":-12.591427,"marketCap":81188580},{"date":"2026-01-16","current":-10.831443,"twenty":-25.942362,"median":-15.72345,"eighty":-12.541142,"marketCap":90330682},{"date":"2026-01-23","current":-11.684272,"twenty":-25.778712,"median":-15.703916,"eighty":-12.481938,"marketCap":97442992},{"date":"2026-01-30","current":-10.264028,"twenty":-25.187337,"median":-15.697179,"eighty":-12.393387,"marketCap":85598629},{"date":"2026-02-06","current":-10.928823,"twenty":-25.019967,"median":-15.609105,"eighty":-12.356869,"marketCap":91142799},{"date":"2026-02-13","current":-10.072648,"twenty":-24.804246,"median":-15.561153,"eighty":-12.271448,"marketCap":84002580},{"date":"2026-02-20","current":-9.694924,"twenty":-24.707543,"median":-15.523057,"eighty":-12.230733,"marketCap":80852483},{"date":"2026-02-27","current":-8.964657,"twenty":-24.644314,"median":-15.470363,"eighty":-11.902275,"marketCap":74762296},{"date":"2026-03-06","current":-7.579668,"twenty":-24.510418,"median":-15.354146,"eighty":-11.744708,"marketCap":63211941},{"date":"2026-03-13","current":-7.26248,"twenty":-24.402557,"median":-15.231581,"eighty":-11.547956,"marketCap":60566700},{"date":"2026-03-20","current":-7.433614,"twenty":-24.380241,"median":-15.204245,"eighty":-11.441777,"marketCap":61993904},{"date":"2026-03-27","current":-7.282524,"twenty":-24.257503,"median":-15.085575,"eighty":-11.16916,"marketCap":60733865},{"date":"2026-04-02","current":-7.741046,"twenty":-23.88557,"median":-14.982381,"eighty":-11.050896,"marketCap":70898177},{"date":"2026-04-10","current":-10.553916,"twenty":-23.442969,"median":-14.91872,"eighty":-10.87741,"marketCap":96660508},{"date":"2026-04-17","current":-9.720712,"twenty":-23.402056,"median":-14.813455,"eighty":-10.831443,"marketCap":89029416},{"date":"2026-04-24","current":-9.544813,"twenty":-23.193773,"median":-14.687648,"eighty":-10.646093,"marketCap":87418407},{"date":"2026-05-01","current":-9.239305,"twenty":-22.896227,"median":-14.687648,"eighty":-10.586353,"marketCap":84620340},{"date":"2026-05-08","current":-9.257913,"twenty":-22.691663,"median":-14.687648,"eighty":-10.553347,"marketCap":84790767},{"date":"2026-05-15","current":-9.276337,"twenty":-22.345765,"median":-14.541015,"eighty":-10.485626,"marketCap":84959499},{"date":"2026-05-22","current":-8.240065,"twenty":-21.746952,"median":-14.447602,"eighty":-10.277122,"marketCap":79702524},{"date":"2026-05-29","current":-8.520578,"twenty":-21.174175,"median":-14.381582,"eighty":-10.186452,"marketCap":82415802},{"date":"2026-06-05","current":-8.196235,"twenty":-21.058875,"median":-14.212199,"eighty":-10.129037,"marketCap":79278575},{"date":"2026-06-12","current":-6.749841,"twenty":-20.902663,"median":-14.132782,"eighty":-10.072567,"marketCap":65288238},{"date":"2026-06-18","current":-5.548895,"twenty":-20.456343,"median":-14.089927,"eighty":-9.868837,"marketCap":53672019},{"date":"2026-06-26","current":-6.48686,"twenty":-20.400553,"median":-13.845611,"eighty":-9.735225,"marketCap":62744540},{"date":"2026-07-02","current":-7.451123,"twenty":-20.222025,"median":-13.758627,"eighty":-9.704482,"marketCap":72071432},{"date":"2026-07-10","current":-6.206347,"twenty":-19.983987,"median":-13.708472,"eighty":-9.577216,"marketCap":60031263},{"date":"2026-07-17","current":-5.452469,"twenty":-19.697598,"median":-13.490877,"eighty":-9.496135,"marketCap":52739330},{"date":"2026-07-24","current":-4.120033,"twenty":-19.489315,"median":-13.45258,"eighty":-9.254191,"marketCap":39851262},{"date":"2026-07-31","current":-4.032372,"twenty":-19.370338,"median":-13.273282,"eighty":-9.151208,"marketCap":39003363},{"date":"2026-08-07","current":-4.865068,"twenty":-19.059597,"median":-13.061127,"eighty":-9.065383,"marketCap":47057663},{"date":"2026-08-14","current":-5.651361,"twenty":-18.858573,"median":-13.012169,"eighty":-8.944511,"marketCap":54663126},{"date":"2026-08-21","current":-6.411685,"twenty":-18.820002,"median":-12.832819,"eighty":-8.692392,"marketCap":65340767}],"updateTime":1787512371852},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EXOZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660492144","title":"Exozymes Says Optimized NCT Process Lifts Manufacturing Productivity 10-Fold","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492144","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492144?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:42","pubTimestamp":1787085774,"startTime":"0","endTime":"0","summary":"Exozymes says optimized NCT process lifts manufacturing productivity 10-foldExozymes reported an optimized N-trans-caffeoyltyramine process that lifted manufacturing productivity by 10x versus its ear","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL1RFpF5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164401","title":"Exozymes FY26 Q2 Net Loss Widens 22% to $2.88 Million; Revenue Remains no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164401","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164401?lang=en_us&edition=fundamental","pubTime":"2026-08-14 03:50","pubTimestamp":1786650656,"startTime":"0","endTime":"0","summary":"Exozymes FY26 Q2 net loss widens 22% to $2.88 million; revenue remains no revenueExozymes posted a net loss of USD 5.25 million for the six months ended June 30, 2026, widening 24.5% year over year.Op","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3qzsmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957943","title":"eXoZymes Menjadwalkan Konferensi Pers Kuartal II 2026 Lewat Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957943","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957943?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:21","pubTimestamp":1786479665,"startTime":"0","endTime":"0","summary":"eXoZymes menjadwalkan konferensi pers kuartal II 2026 lewat webinarExozymes menjadwalkan webinar pembaruan kinerja kuartal II 2026 pada Kamis, 20 Agustus 2026, pukul 17.00 ET.Rilis pers hasil kuartal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7kVKnt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651469466","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:35 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2651469466","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651469466?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:35","pubTimestamp":1784122508,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:35 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nAQN2M82BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648718526","title":"Exozymes Prices Registered Direct Offering at USD 18 Per Unit, Raising USD 639,990 Gross","url":"https://stock-news.laohu8.com/highlight/detail?id=2648718526","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648718526?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:32","pubTimestamp":1782937966,"startTime":"0","endTime":"0","summary":"Exozymes prices registered direct offering at USD 18 per unit, raising USD 639,990 grossExozymes priced a placement of 35,555 units at USD 18 per unit, each with two common shares and one warrant.Deal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL6L1Xsl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4127","MDBH","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646356820","title":"Exozymes Wins USD 2.03 Million NIH Grant for Cannabinoid Analog Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2646356820","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646356820?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:03","pubTimestamp":1782468201,"startTime":"0","endTime":"0","summary":"eXoZymes wins USD 2.03 million NIH grant for cannabinoid analog developmentExozymes secured a $2.03 million NIH NIGMS Phase IIB SBIR grant to advance rare cannabinoids and engineered cannabinoid analo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL8f8Y2T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646845561","title":"Exozymes Wins NIH Grant Worth $2.03 Million for Cannabinoid Analog Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2646845561","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646845561?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:10","pubTimestamp":1782331823,"startTime":"0","endTime":"0","summary":"Exozymes wins NIH grant worth $2.03 million for cannabinoid analog developmentExozymes won a Phase IIB SBIR grant worth $2.03 million from the NIH’s National Institute of General Medical Sciences.Two-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL3Hv7KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644729258","title":"eXoZymes closes USD 5.95 million follow-on offering of stock and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2644729258","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644729258?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:10","pubTimestamp":1781727020,"startTime":"0","endTime":"0","summary":"Exozymes closed an underwritten public offering raising about USD 5.95 million in gross proceeds from common stock and warrants.Issued 330,575 units; each unit included two common shares priced at USD 8.99 plus one warrant priced at USD 0.02.Warrants become exercisable one year from issuance at USD 11.24 per share; expire five years from issuance.Proceeds earmarked for N-trans-caffeoyltyramine development and commercialization, broader pipeline work, R&D, working capital.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLc0pW2r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641928487","title":"EXoZymes Prices $5.3 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2641928487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641928487?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:52","pubTimestamp":1780926759,"startTime":"0","endTime":"0","summary":"EXoZymes  has priced its public offering of units, consisting of two shares of common stock and one common stock purchase warrant, at $18 per unit, with estimated gross proceeds of $5.3 million, the company said Monday.The company also granted the underwriter a 45-day option to purchase up to 44,420 units at the offering price, it said.Proceeds will be used to further develop N-trans-caffeoyltyramine opportunities associated with EXoZymes' NCT business, the company said.The offering is slated to close on Tuesday.Shares of the company were up 5.4% in early Monday trading.Price: 9.49, Change: +0.49, Percent Change: +5.44","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641482458","title":"eXoZymes prices 592,270 shares at $18.00 in public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2641482458","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641482458?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:20","pubTimestamp":1780924853,"startTime":"0","endTime":"0","summary":"eXoZymes (EXOZ) announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exozymes-prices-592270-shares-at-18-00-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exozymes-prices-592270-shares-at-18-00-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641482819","title":"eXoZymes prices public offering of stock-warrant units at $18, raising $5.33 million gross","url":"https://stock-news.laohu8.com/highlight/detail?id=2641482819","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641482819?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:00","pubTimestamp":1780923631,"startTime":"0","endTime":"0","summary":"Exozymes priced a public offering of units at USD 18 each, with each unit comprising two common shares and one common stock purchase warrant.Deal includes 592,270 common shares, 296,135 warrants; gross proceeds expected at about USD 5.33 million; closing set for June 9, 2026.Warrants become exercisable one year from the offering, carry an exercise price of USD 11.24 per share, expire five years from issuance.Warrants can be redeemed at USD 0.01 per underlying share if the stock trades at USD 17.98 or higher on 20 of 30 trading days.Net proceeds earmarked for N-trans-caffeoyltyramine programs, R&D, working capital, corporate purposes, capital expenditures.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL5jqQ5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635372894","title":"Exozymes Q1 FY26 net loss widens 27.7% to $2.37 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635372894","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635372894?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:51","pubTimestamp":1778788293,"startTime":"0","endTime":"0","summary":"Exozymes posted a net loss of USD 2.37 million for the three months ended March 31, 2026, widening 27.7% from a year earlier.Operating loss widened 22.4% to USD 2.39 million on total operating costs that rose 22.4% to USD 2.39 million.Research and development costs nearly doubled to USD 1.12 million, while general and administrative costs fell 8% to USD 1.27 million.Cash and cash equivalents dropped 52.5% to USD 1.44 million as operating activities used USD 1.52 million in cash; working capital totaled about USD 507,586.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL8ylCQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633739071","title":"eXoZymes announces graduation from Shell GameChanger Accelerator","url":"https://stock-news.laohu8.com/highlight/detail?id=2633739071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633739071?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:15","pubTimestamp":1778181317,"startTime":"0","endTime":"0","summary":"eXoZymes (EXOZ) announced its graduation from the Shell GameChanger Accelerator, a multimillion-dollar, multiyear program developed in collaboratio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exozymes-announces-graduation-from-shell-gamechanger-accelerator-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exozymes-announces-graduation-from-shell-gamechanger-accelerator-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148649","title":"Exozymes CSO Tyler Korman disposes of USD 15,424 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148649","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148649?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:31","pubTimestamp":1775853081,"startTime":"0","endTime":"0","summary":"Exozymes Chief Scientific Officer Tyler Paz Korman sold 1,500 shares in two transactions dated April 8-9.Sales priced at USD 10.04 per share, USD 10.53 per share.Directly owned stake stood at 729,123 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL5DNyXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Exozymes CSO Tyler Korman disposes of USD 15,424 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118479","title":"eXoZymes CCO says NCTx targets supplement launch for NCT, eyes pharma options","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118479","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118479?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:10","pubTimestamp":1775826619,"startTime":"0","endTime":"0","summary":"eXoZymes CCO Damien Perriman used Grow Everything podcast interview to outline commercialization strategy for NCTx, company first spinout focused on NCT.Perriman framed NCTx as vehicle to move NCT into market while eXoZymes concentrates on cell-free biomanufacturing process development.Interview cited third-party validation with Cayman Chemical, where NCT process was transferred, scaled 100-fold, reaching about 99% conversion.Validation run also achieved 99.6% purity, supporting tech-transfer claims for cell-free platform.Perriman said initial route targets supplement market for NCT while pharmaceutical options remain under evaluation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL1jB2f5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626001153","title":"BRIEF-Exozymes Inc - Announces Common Stock Offering - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2626001153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626001153?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:04","pubTimestamp":1775772266,"startTime":"0","endTime":"0","summary":"BRIEF-Exozymes Inc - Announces Common Stock Offering - SEC FilingApril 9 (Reuters) - eXoZymes Inc EXOZ.O:EXOZYMES INC - ANNOUNCES COMMON STOCK OFFERING - SEC FILINGSource text: [ID:n0001493152-26-015919]Further company coverage: EXOZ.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S1BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626653973","title":"Exozymes files Form 3 for Chief Commercial Officer Damien Perriman","url":"https://stock-news.laohu8.com/highlight/detail?id=2626653973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626653973?lang=en_us&edition=fundamental","pubTime":"2026-04-09 07:20","pubTimestamp":1775690442,"startTime":"0","endTime":"0","summary":"Exozymes filed an initial beneficial ownership statement naming Damien Perriman as chief commercial officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL6XVnJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530472","title":"eXoZymes Inc. - Common Stock Q4 EPS $(0.31)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530472","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530472?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:36","pubTimestamp":1774989390,"startTime":"0","endTime":"0","summary":"eXoZymes Inc. - Common Stock (NASDAQ:EXOZ) reported quarterly losses of $(0.31) per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51585108/exozymes-inc-common-stock-q4-eps-0-31","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"eXoZymes Inc. - Common Stock Q4 EPS $(0.31)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624168537","title":"MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2624168537","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624168537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:05","pubTimestamp":1774987500,"startTime":"0","endTime":"0","summary":"Management to Host Conference Call Today at 4:30 p.m. ETAddison, TX, March  31, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launchi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3266015/0/en/MDB-Capital-Holdings-Provides-2025-Full-Year-Update-and-Shareholder-Letter.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2286300806.USD","LU1951198990.SGD","LU2272731782.SGD","BK4613","LU0154245756.USD","LU1992135472.HKD","LU2357305700.SGD","LU1923623000.USD","LU0154245673.USD","BK4585","BK4588","LU1861220033.SGD","BK4116","LU1720051017.SGD","LU0353189680.USD","LU0082616367.USD","LU1548497426.USD","SG9999000418.SGD","LU1951200564.SGD","MDB","EXOZ","LU0823434740.USD","MDBX","LU2087625088.SGD","BK4607","LU0390134368.USD","LU0823434583.USD","LU0719512351.SGD","BK4139","LU0353189763.USD","LU2272731600.USD","MDBH","BK4608","LU1992135399.USD","BK4127","LU1720051108.HKD","LU1861215975.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623377324","title":"Exozymes FY25 net loss widens 56.3% to $9.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623377324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623377324?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:31","pubTimestamp":1774906294,"startTime":"0","endTime":"0","summary":"Exozymes net loss widened 56.3% to $9.2 million in fiscal 2025.Operating loss expanded 63.8% to $9.7 million as operating costs climbed 63.8% to $9.7 million.Cash and cash equivalents fell 68.7% to $3 million, while working capital shrank to $2.4 million.Company highlighted an October 2024 Department of Defense BioMADE cost-share grant of about $1 million and a March 2025 NIH BioClick grant of $283,805, while warning of substantial doubt about its ability to continue as a going concern.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2tcBhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXOZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}